MUC1-positive circulating tumor cells and MUC1 protein predict chemotherapeutic efficacy in the treatment of metastatic breast cancer
Authors:
- Ying YanYYYing Yan
- Xiang-Yi WangXWXiang-Yi Wang
- Yuan-Li LuYLYuan-Li Lu
- Yan-Hua YuanYYYan-Hua Yuan
- Jun JiaJJJun Jia
- Jun RenJRJun Ren
Open Access
- 5 January 2011
- journal article
- Published by Editorial Office of Chinese Journal of Cancer in Chinese Journal of Cancer
- Vol. 30 (1) , 54-61
Abstract
Chemotherapy plays an important role in the treatment of metastatic breast cancer. It is important to monitor chemotherapeutic efficacy, to find a simple and efficient tool to guide treatment, and to predict the efficacy of treatment in a timely and accurate manner. This study aimed to detect mucin-1 (MUC1)– positive circulating tumor cells and MUC1 protein in the peripheral blood of patients with metastatic breast cancer and to investigate their relationship to chemotherapeutic efficacy. MUC1 mRNA was detected in the peripheral blood of 34 patients with newly diagnosed metastatic breast cancer by reverse transcription-polymerase chain reaction. The positive rates of MUC1 mRNA were 88.2% before chemotherapy and 70.6% after chemotherapy, without a significant difference (P = 0.564); MUC1 mRNA expression before chemotherapy had no correlation with treatment effectiveness (P = 0.281). The response rate of MUC1 mRNA-negative patients after first-cycle chemotherapy was significantly higher (P = 0.009) and the progression-free survival (PFS) was clearly longer than those of MUC1 mRNA-positive patients (P = 0.095). MUC1 protein in peripheral blood plasma was detected by an ELISA competitive inhibition assay. The patients with decreased MUC1 protein after chemotherapy had a significantly longer PFS than those with elevated MUC1 protein (P = 0.044). These results indicate that the outcomes of MUC1 mRNA-negative patients after chemotherapy are better than those of MUC1 mRNA-positive patients. In addition, patients with decreased expression of MUC1 protein have a better PFS.Keywords
This publication has 25 references indexed in Scilit:
- Multi-center study evaluating circulating tumor cells as a surrogate for response to treatment and overall survival in metastatic breast cancerBreast Cancer, 2009
- Circulating Tumor Cells: A Novel Prognostic Factor for Newly Diagnosed Metastatic Breast CancerJournal of Clinical Oncology, 2005
- Prevalence of CD44+/CD24−/low Cells in Breast Cancer May Not Be Associated with Clinical Outcome but May Favor Distant MetastasisClinical Cancer Research, 2005
- Tumor Cells Circulate in the Peripheral Blood of All Major Carcinomas but not in Healthy Subjects or Patients With Nonmalignant DiseasesClinical Cancer Research, 2004
- Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast CancerNew England Journal of Medicine, 2004
- Identification of carcinoma cells in peripheral blood samples of patients with advanced breast carcinoma using RT-PCR amplification of CK7 and MUC1The Breast, 2004
- Epithelial progenitor cell lines as models of normal breast morphogenesis and neoplasiaCell Proliferation, 2003
- Detection of circulating breast tumor cells by differential expression of marker genes.2002
- Circulating Breast Cancer Cells Are Frequently ApoptoticThe American Journal of Pathology, 2001
- UK and USA breast cancer deaths down 25% in year 2000 at ages 20–69 yearsThe Lancet, 2000